Published in Front Oncol on May 19, 2017
The DNA damage response: making it safe to play with knives. Mol Cell (2010) 16.13
Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. Science (1998) 8.74
ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol (2005) 8.27
Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell (2003) 7.48
Double-strand break end resection and repair pathway choice. Annu Rev Genet (2011) 7.31
Maintaining genome stability at the replication fork. Nat Rev Mol Cell Biol (2010) 5.88
Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A (2000) 5.64
The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol (2013) 5.33
Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol (2008) 5.10
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
DNA double-strand break repair: from mechanistic understanding to cancer treatment. DNA Repair (Amst) (2007) 3.69
A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol (2008) 3.07
ATR-dependent phosphorylation and activation of ATM in response to UV treatment or replication fork stalling. EMBO J (2006) 3.05
Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol (2011) 2.85
Rapid activation of ATR by ionizing radiation requires ATM and Mre11. J Biol Chem (2006) 2.76
DNA repair dysregulation from cancer driver to therapeutic target. Nat Rev Cancer (2012) 2.70
Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett (2004) 2.35
ATM regulates ATR chromatin loading in response to DNA double-strand breaks. J Exp Med (2006) 2.31
The influence of heterochromatin on DNA double strand break repair: Getting the strong, silent type to relax. DNA Repair (Amst) (2010) 2.24
Comparison of nonhomologous end joining and homologous recombination in human cells. DNA Repair (Amst) (2008) 2.11
Targeting ATR and Chk1 kinases for cancer treatment: a new model for new (and old) drugs. Mol Oncol (2011) 2.07
DNA double-strand break repair pathway choice is directed by distinct MRE11 nuclease activities. Mol Cell (2013) 1.93
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood (2008) 1.76
ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes Dev (2013) 1.70
Claspin and the activated form of ATR-ATRIP collaborate in the activation of Chk1. J Biol Chem (2004) 1.70
Ataxia-telangiectasia mutated (ATM)-dependent activation of ATR occurs through phosphorylation of TopBP1 by ATM. J Biol Chem (2007) 1.61
Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene (2007) 1.57
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma. Blood (2012) 1.56
Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol Sci (2011) 1.55
Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol (2011) 1.30
DNA replication stress: causes, resolution and disease. Exp Cell Res (2014) 1.23
A double-strand break within a yeast artificial chromosome (YAC) containing human DNA can result in YAC loss, deletion or cell lethality. Mol Cell Biol (1996) 1.19
Activation of DSB processing requires phosphorylation of CtIP by ATR. Mol Cell (2012) 1.16
Targeting DNA damage response in cancer therapy. Cancer Sci (2014) 1.16
Pathway choice in DNA double strand break repair: observations of a balancing act. Genome Integr (2012) 1.13
Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia (2011) 1.08
Interplay between ATM and ATR in the regulation of common fragile site stability. Oncogene (2007) 1.04
Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 1.04
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov (2015) 1.01
The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther (2012) 0.92
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood (2015) 0.92
A Small-Molecule Inhibitor of RAD51 Reduces Homologous Recombination and Sensitizes Multiple Myeloma Cells to Doxorubicin. Front Oncol (2014) 0.86
DNA repair targeted therapy: The past or future of cancer treatment? Pharmacol Ther (2016) 0.84
Treatment for patients with newly diagnosed multiple myeloma in 2015. Blood Rev (2015) 0.84
Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res (2015) 0.83
Deregulation of DNA double-strand break repair in multiple myeloma: implications for genome stability. PLoS One (2015) 0.82
Naked replication forks break apRPArt. Cell (2013) 0.79
Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair. Oncotarget (2016) 0.76